Publications
Where expertise meets impact
Berry doesn’t just follow industry standards — we set them. Our team of award-winning statisticians, journal editors, and regulatory advisors leads the field in Bayesian and adaptive trial design. With research published in The New England Journal of Medicine, JAMA, and The Lancet, we’re driving innovation where it matters most.
Over 90% of our scientists published influential work this past year, advancing adaptive, Bayesian, and platform trial methodology. Our blend of academic rigor, regulatory insight, and real-world experience makes Berry a true authority in modern clinical trials.
Explore our most impactful peer-reviewed publications below.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
American Heart Association Journal
Neuroscience
Stroke
Letter by Berry et al Regarding Article, "Utility-Weighted Modified Rankin Scale as Primary Outcome in Stroke Trials: A Simulation Study"
October 24, 2018
2018
DOI: 10.1161/STROKEAHA.118.022198
Wiley Online Library
Neuroscience
Alzheimer's Disease
A novel cognitive disease progression model for clinical trials in autosomal-dominant Alzheimer's disease
May 14, 2018
2018
DOI: 10.1002/sim.7811
Clinical Cancer Research
Oncology
Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE
February 15, 2018
2018
DOI: 10.1158/1078-0432.CCR-17-0764
ATS
Sepsis
Rationale and Design of an Adaptive Phase 2b/3 Clinical Trial of Selepressin for Adults in Septic Shock. Selepressin Evaluation Programme for Sepsis-induced Shock-Adaptive Clinical Trial
November 14, 2017
2017
DOI: 10.1513/AnnalsATS.201708-669SD
The New England Journal of Medicine
Neuroscience
Stroke
Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct
November 11, 2017
2017
DOI: 10.1056/NEJMoa1706442
JAMA Oncology
Oncology
Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia: A Meta-analysis
July 13, 2017
2017
DOI: 10.1001/jamaoncol.2017.0580
Alzheimer's Association
Neuroscience
Alzheimer's Disease
The DIAN-TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression model
January 13, 2017
2017
DOI: 10.1016/j.jalz.2016.07.005
Alzheimer's Research & Therapy
Neuroscience
Alzheimer's Disease
ABT-126 monotherapy in mild-to-moderate Alzheimer's dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension
October 18, 2016
2016
DOI: 10.1186/s13195-016-0210-1.
No results found.
There are no results with this criteria. Try changing your search.